Table 2 Clinical and lab features of untreated TA patients with positive or negative ASO

Female, n(%)

11 (84.6)

49 (78.7)

0.720

Age of onset (year)

29.5 ± 10.0

33.5 ± 12.5

0.281

Disease duration (month)

6.0 (1.0, 102.0)

48.0 (12.0, 168.0)

0.081

BMI (kg/m²)

23.3 ± 3.5

22.8 ± 3.5

0.641

Arteriosclerosis, n(%)

3 (23.1)

30 (49.2)

0.086

Hypertension, n(%)

5 (38.5)

13 (21.3)

0.191

T2DM, n(%)

0 (0.0)

4 (6.6)

0.342

Smoker, n(%)

2 (15.4)

11 (18.0)

0.820

Heart failure, n(%)

4 (30.8)

9 (14.8)

0.168

AF, n(%)

0 (0.0)

0 (0.0)

–

Aneurysms, n(%)

3 (23.1)

13 (21.3)

0.966

Dizziness, n(%)

7 (53.9)

27 (44.3)

0.529

Headache, n(%)

2 (15.4)

11 (18.0)

0.820

Asymmetry in BP, n(%)

6 (46.2)

23 (37.7)

0.571

Pulseless, n(%)

4 (30.8)

13 (21.3)

0.462

Chest tightness, n(%)

5 (38.5)

17 (27.9)

0.448

Chest pain, n(%)

2 (15.4)

15 (24.6)

0.474

Palpitations, n(%)

3 (23.1)

4 (6.6)

0.065

Carotidynia, n(%)

1 (7.7)

4 (6.6)

0.882

Erythema nodosum, n(%)

1 (7.7)

1 (1.6)

0.222

Blurred vision, n(%)

0 (0.0)

4 (6.6)

0.342

Fever, n(%)

3 (23.1)

9 (14.8)

0.460

Fatigue, n(%)

4 (30.8)

14 (23.0)

0.551

Weight loss, n(%)

2 (15.4)

3 (4.9)

0.172

 I

3 (23.1)

16 (26.2)

0.086

 IIa

1 (7.7)

3 (7.7)

0.688

 IIb

3 (23.1)

9 (14.8)

0.460

 III

1 (7.7)

4 (6.6)

0.882

 IV

1 (7.7)

1 (1.6)

0.222

 V

4 (30.8)

25 (41.0)

0.493

 P+

3 (23.1)

7 (11.5)

0.267

 C+

1 (7.7)

14 (23.0)

0.214